NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: V
Post# of 111
(Total Views: 292)
Posted On: 10/29/2019 4:19:55 PM
NetworkNewsBreaks – VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) Enters Technology and Research Partnership with CB2 Insights Inc. (CSE: CBII) (OTCQB: CBIIF)
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF), an Ontario-based cannabis company recognized for its premium products and services, has entered into a technology and multi-phase research agreement with CB2 Insights Inc. (CSE: CBII) (OTCQB: CBIIF) (“CB2”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community. Under the agreement, CB2 will assist in the development of VIVO’s global medical product development strategy. CB2 will integrate its Clinical Data Management Software (“CDMS”) and Electronic Data Capture (“EDC”) tools to establish a better understanding of VIVO’s current medical patient registry, and the companies will collaborate on a comprehensive research strategy to validate the safety and efficacy of current products. “CB2’s global experience in clinical research and technology will enable VIVO to enhance our understanding of Canadian medical patients. This will facilitate our uncovering of new ways to meet the expectations of our current patients and will help inform our international growth plans,” VIVO CEO Barry Fishman said in the news release. “At VIVO, our purpose is to help patients achieve a positive quality of life with cannabis. We look forward to utilizing our partnership with CB2 to further bring real world evidence to the medical cannabis industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF), an Ontario-based cannabis company recognized for its premium products and services, has entered into a technology and multi-phase research agreement with CB2 Insights Inc. (CSE: CBII) (OTCQB: CBIIF) (“CB2”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community. Under the agreement, CB2 will assist in the development of VIVO’s global medical product development strategy. CB2 will integrate its Clinical Data Management Software (“CDMS”) and Electronic Data Capture (“EDC”) tools to establish a better understanding of VIVO’s current medical patient registry, and the companies will collaborate on a comprehensive research strategy to validate the safety and efficacy of current products. “CB2’s global experience in clinical research and technology will enable VIVO to enhance our understanding of Canadian medical patients. This will facilitate our uncovering of new ways to meet the expectations of our current patients and will help inform our international growth plans,” VIVO CEO Barry Fishman said in the news release. “At VIVO, our purpose is to help patients achieve a positive quality of life with cannabis. We look forward to utilizing our partnership with CB2 to further bring real world evidence to the medical cannabis industry.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)